治疗后SPECT/CT对177Lu-PSMA-617放射性药物治疗期间患者管理的影响
该回顾性研究纳入122例接受177Lu-PSMA放射性药物治疗的患者,治疗后24小时行SPECT/CT,评估其对患者管理的影响。49%(n=60)患者管理发生改变,其中57%(n=34)因疾病进展、40%(n=24)因治疗反应、3%(n=2)为其他原因;进展相关改变多发生于第2和第4周期后,反应相关改变多发生于第3和第4周期后。作者所在中心将治疗后SPECT/CT整合入常规PSMA放射性药物治疗方案可辅助患者管理。
要点
- 122例接受177Lu-PSMA放射性药物治疗的患者中,49%(n=60)因治疗后SPECT/CT发生管理改变。
- 管理改变中57%(n=34)因疾病进展,40%(n=24)因治疗反应,3%(n=2)为其他原因。
- 进展相关改变多发生于第2和第4周期后,反应相关改变多发生于第3和第4周期后。
核心结论
- 作者所在中心49%的患者基于治疗后SPECT/CT发生管理改变,多数改变发生于第2和第4周期。
- 作者认为将治疗后SPECT/CT整合入常规PSMA放射性药物治疗方案可辅助患者管理。
研究设计与样本
- 回顾性研究,纳入122例接受177Lu-PSMA放射性药物治疗的患者,治疗后24小时行SPECT/CT。
- 对每个周期进行定性疗效评估,并查阅病历评估治疗后SPECT/CT对患者管理的影响。
- 管理改变分为基于疾病进展和基于治疗反应的改变,并记录发生的具体周期;同时评估其他管理改变。
主要发现
- 在122例连续纳入的患者中,各治疗周期视觉评估显示42%-56%的患者为疾病稳定,19%-39%的患者为治疗反应。
- 49%(n=60)的患者发生管理改变,其中57%(n=34)因疾病进展,40%(n=24)因治疗反应,3%(n=2)为其他改变。
- 因疾病进展的管理改变多发生于第2和第4周期后,因治疗反应的管理改变多发生于第3和第4周期后。
临床怎么用
- 作者所在中心基于治疗后SPECT/CT,49%的患者发生管理改变,多数改变发生于第2和第4周期。
- 作者认为将治疗后SPECT/CT整合入常规PSMA放射性药物治疗方案可辅助患者管理。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
177Lu can be imaged after administration using SPECT/CT. Most work to date has focused on using posttreatment imaging to measure normal organ and tumor dose. We aimed to assess the impact of posttreatment SPECT/CT on the management of patients undergoing 177Lu-prostate-specific membrane antigen (PSMA) radiopharmaceutical therapy (RPT). Methods: In this retrospective study, 122 patients underwent PSMA RPT with subsequent SPECT/CT 24 h after treatment. We determined a qualitative response at each cycle and reviewed patient charts to assess the impact that posttreatment SPECT/CT had on patient management. Changes in patient management were classified as changes on the basis of progression and response, and specific cycles when they occurred were noted. Miscellaneous changes in patient management were also evaluated. Results: Among the 122 consecutive patients examined, 42%-56% exhibited stable disease, whereas 19%-39% of patients exhibited response on visual assessment across treatment cycles. In total, 49% (n = 60) of patients experienced changes in management, of which 57% (n = 34) were due to progression, 40% (n = 24) were due to response, and 3% (n = 2) were due to miscellaneous changes. Changes due to disease progression were observed mostly after cycles 2 and 4. Changes due to response to RPT occurred mostly after cycles 3 and 4. Conclusion: At our center, 49% of patients experienced changes in management based on posttreatment SPECT/CT, and most of these changes occurred at cycles 2 and 4. Integrating posttreatment SPECT/CT into routine PSMA RPT protocols can aid in patient management.
引用
- Yadav S, Lowery B, Tuchayi AM, et al. Impact of Posttreatment SPECT/CT on Patient Management During 177Lu-PSMA-617 Radiopharmaceutical Therapy. J Nucl Med. 2024. PMID: 39117452. doi:10.2967/jnumed.124.267955
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。